Move Over Henry Cavill & Tom Hardy – Regé-Jean Page Is The New Bond?

Regé-Jean Page is fan favourite to take up the coveted title of MI5 agent 007 aka James Bond

The crown of the traditionally suave, and now gritty and hardened super-spy James Bond, is set to transfer yet again. James Bond’s legacy endures in how the series has embraced the changing times. Take a look at the storylines for example, where Bond explored all kinds of personas from a sophisticated ladies’ man in espionage thrillers, to a campy effects heavy sleuth (read Die Another Day), to a darker and grungier agent that has problems with authority (Casino Royale, Skyfall).

Bond’s latest ventures (post Casino Royale) on the big screen have often asked the question of the durability of one-man driven agency, standing in the face of emerging evil that is smarter and hi-tech, threatening to take down civilization. Existential questions aside, with Daniel Craig’s departure from the series after his fifth venture as the steely-eyed spook, quite a few names have been doing the rounds.

Watch: Regé-Jean Page Addresses Those James Bond Rumors

Related: Robert Pattinson As James Bond Will Make You Doubt Daniel Craig

Henry Cavill

Starting off with Henry Cavill – who’s proven his chops as a leading man with credits like Man of Steel and The Witcher under his belt. He is also not new to the spy genre with starring roles in Mission Impossible and The Man from U.N.C.L.E.

Henry Cavill 'would absolutely jump at the opportunity' to be the next James Bond

'At this stage, it’s all up in the air. We’ll see what happens'

(via @GQMagazine | https://t.co/pMePzdXlLK) pic.twitter.com/DnS6nwyIp7

— Fandom (@getFANDOM) September 28, 2020

Cavill’s odds have been put to rest by Dr. Ian Kinane, editor of believe it or not, a journal on James Bond studies. In his opinion, Cavill has become too popular with his meteoric rise, while the Bond series has been seen to prefer relatively unknown stars. For one, Daniel Craig was relatively unknown at the time with roles in movies like Layer Cake and Tomb Raider. But the Bond series is what made him a household name and also drawn critical acclaim for the series.

Tom Hardy

Tom Hardy, a fan favourite who has also graced us with blockbusters is an unlikely candidate either. Hardy’s manic presence has been seen in movies like Mad Max and Legend, while his qualities that exude Bond-like confidence were seen in Inception and This Means War. Back in 2018, the star had cheekily hinted at being in the race for Bond when he posted hints on his Instagram.

Tom Hardy was just asked if he could be James Bond with Nolan directing & he said "If I mention it, it’s gone." Would he be a great Bond? pic.twitter.com/RGhPeBR6oM

— GOAT Movies (@GOATMoviePod) January 17, 2017

But given Hardy’s track record, and carving his own niche in both industries (British and American), it seems like he too could be too big to fit into Bond’s shoes.

Regé-Jean Page

Amid all this speculation, another name has been added to the list – Regé-Jean Page for Bond. Page, along with the likes of Idris Elba and Daniel Kaluuya are in a slim list of non-white contenders that could play the lead. According to an interview with producer Barbara Broccoli, the role would have to be reimagined which includes the actor being non-white and non-British.

Now, where does that put Page? Speculation on his role began after his exit from the Netflix series, Bridgerton. The 31-year-old has relatively no experience when it comes to being cast as a lead for a major movie – which works in his favour. But given the chance would he take it? In an interview with Jimmy Fallon, he deftly avoided the question by commenting on how honoured he felt to even be included in the gossip.

“You walk out in someone else’s shoes, and I like to do that quite literally. The first thing I do on a job is ask for the shoes or the boots so I can walk around them at home while I’m working and build from the ground up.”@whowhatwear https://t.co/CWzuELtrS8#Bridgerton pic.twitter.com/qwpyTc3Ysg

— Regé-Jean Page (@regejean) January 7, 2021

Does that mean he’s a shoo-in for the role? Talent aside, a lot of polls conducted show that the audience has been calling for an actor of colour to replace the typecasting. Along with this, the likes of Idris Elba for Bond, have also been discussed at great lengths. Age aside, Elba is not impressed with the lip-service act that casting him would do for the franchise.

Regé-Jean Page’s chances to play James Bond on the other hand are much higher given the decision for studio executives to make blockbuster gold, the likes of the MCU or even the Mission Impossible franchise. Could Page be the youngest to be cast in the role? Whatever the studio’s decision, it has never faltered from introducing a fresh face. Maybe Regé-Jean Page’s addition to the Bond mix finally spans the race bridge and puts all the speculation to rest!

The post Move Over Henry Cavill & Tom Hardy – Regé-Jean Page Is The New Bond? appeared first on DKODING.

from https://www.dkoding.in/entertainment/hollywood/henry-cavill-tom-hardy-rege-jean-page-james-bond/
via Dkoding RSS Feed

Share:

Read More

Grateful for the debut-salute to Mamata, Mukul-Putra’s talk of ‘returning home’ again

https://ift.tt/eA8V8J

Kolkata: Once again, Subhranshu Roy, son of Mukul Roy, instigated the rumors of a change of party. Said, ‘I am grateful to Abhishek. Salute Mamata Banerjee. ‘ As the praise for Mamata-Abhishek came to Shuvrangshu’s face again, the speculation about Mukul Roy’s unwritten arrival in the grassroots got more air. That night, Shuvrangshu told NEWS 18 Bangla, ‘Abhishek has great respect for my mother. I am grateful to Abhishek Banerjee for standing by me like this. The Chief Minister has inquired about my father’s health. I am also grateful to her. My mother may have to atone for my forgetfulness. Abhishek has searched for his mother as many times as he has seen in the past.

After that, Mukul’s son praised Abhishek and said, ‘When I saw Abhishek for the first time, he used to ask me how is my aunt? We grew up together. He is a national figure today. I lost. Even after that he has searched that way. That is why I am eternally grateful. The Chief Minister is always looking for whether his father has been vaccinated or what he is eating now.

He also took the religious politics of BJP in Bengal by one hand. “We ignored them five months ago,” he said. Many are wearing sheets for my mother today. Discrimination in Bengali politics was not right at all. My priority is my mother.

Apart from criticizing the BJP, Shuvrangshu Roy also praised the Chief Minister. He said, ‘A party has come to the power of public support. Before criticizing him, we should think about why we lost. The way the chief minister acted in the covid situation, the way the chief minister acted with Yas, should be saluted. ‘

By the way, some sections of the political circles are saying that it is not Shuvrangshu, all these words are actually Mukul Roy’s ‘words of mind’ Mukul’s recent activities, disillusionment with the BJP, Abhishek Bandyopadhyay’s hospital visit to see Mukul’s ailing wife, Mukul’s son Shuvrangshur’s Abhishek-Bandana, above all the Mukul Roy-Dilip Ghosh clash, all in all, the state politics squabbles over Mukul Roy. However, Mukul Roy himself has not yet spoken of returning to the grassroots. However, the path that is being paved is becoming increasingly clear.

In a close circle, Mukul himself said, ‘Abhishek and Shuvrangshu are childhood friends. They know each other well. Such a relationship is normal between them. That means the message is clear. A section of the political circles say that Mukul, who once left the grassroots due to a conflict with Abhishek, has in fact made the message of his mind clear with such a soft tone about him.

—- Kamalika Sengupta

Source link

from https://www.thetimesofbengal.com/2021/06/04/grateful-for-the-debut-salute-to-mamata-mukul-putras-talk-of-returning-home-again/
via The Times of Bengal | An exclusive 24*7 daily news portal RSS Feed

Share:

Read More

Not Modi, Mamata’s picture in the vaccine certificate bought with state money!

https://ift.tt/eA8V8J

This time Mamata Banerjee’s picture in Covid 19 Vaccine certificate! On behalf of the state, the ticker certificate will have a picture of Chief Minister Mamata Banerjee. So far, the certificate issued from the Co-Win portal has a picture of Prime Minister Narendra Modi. But since the vaccine is now being given on behalf of the state, i.e. in the sense of purchase from the state treasury, the certificates of the Chief Minister of the state will be in those certificates.

Source link

from https://www.thetimesofbengal.com/2021/06/04/not-modi-mamatas-picture-in-the-vaccine-certificate-bought-with-state-money/
via The Times of Bengal | An exclusive 24*7 daily news portal RSS Feed

Share:

Read More

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Business Wire India

• FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH.
• Boehringer Ingelheim’s focus on the development of next generation NASH treatments builds on its strong track record of bringing new therapies to people with cardiometabolic diseases.

 

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH). The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis (F2/F3) with and without diabetes.

 

“The FDA Fast Track Designation for our dual agonist is an important step forward in addressing the high unmet medical need among the up to 444 million adults estimated to be living with NASH,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “Together with our partner Zealand Pharma, we look forward to working closely with the FDA as we explore the potential of the GLP-1/glucagon agonist to improve outcomes for adults with NASH.”

 

“Boehringer Ingelheim and Zealand Pharma are committed to delivering innovative solutions that address public health challenges of cardiometabolic diseases, including NASH,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “By combining Boehringer Ingelheim’s expertise in drug development in the cardio-metabolic area with our strength in the discovery of innovative peptide-based medicines, we have the potential to bring forward a novel therapy option in an area with limited available treatments.”

 

The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. It is also being investigated as a potential treatment option for adults living with diabetes and for adults living with obesity. It is part of Boehringer Ingelheim’s research and development portfolio in the cardiometabolic disease areas.

 

Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/fast-track-designation-nash

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005582/en/

The content is by Business Wire India. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.

The post Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH appeared first on DKODING.

from https://www.dkoding.in/press-release/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation-for-investigational-treatment-for-nash/
via Dkoding RSS Feed

Share:

Read More

COMPUTEX Forum Day 1: Deep Diving into AI and AIoT

Business Wire India

According to Gartner, by 2023, one-third of companies that have implemented IoT will also have implemented AI in conjunction with at least one IoT project. Data generated from IoT devices will be integrated in various vertical applications and eventually be applied to smart factories, smart healthcare, smart transportation, and smart cities. The first two sessions of COMPUTEX Forum organized by TAITRA, "AIoT Evolution" and "AI Empowerment,” were held on June 2. Top speakers from Micron Technology, Intel, Supermicro, NVIDIA, NXP Semiconductors, Arm, Delta Electronics, and Check Point Software were among the lineup to deep dive into the infinite possibilities of AIoT and AI.

 

Micron Technology: Driving AI innovation with storage in the new era of data intensive computing

 

President and CEO of Micron Technology Sanjay Mehrotra pointed out that the world is at the dawn of a new age of data intensive computing. AI and 5G are the two major drivers of this age. With the rapid growth of AI applications, accompanied by numerous challenges, Micron Technology will continue to build a reliable, systematic infrastructure based on memory and storage for a better AI future.

 

Intel: Embracing infinite computing possibilities with next-gen AI processor

 

Nash Palaniswamy, Vice President of Intel’s Sales and Marketing Group and General Manager of AI, HPC, Datacenter Accelerators Solutions and Sales, addressed the possibilities of 3rd Gen Intel Xeon Scalable Processor. The latest generation of Xeon is capable of fulfilling AI and high-performance computing needs. Supported by close partnerships and deep integrations with the world’s software leaders and solution providers, Intel delivers fast, consistent, and secure solutions that people trust.

 

Supermicro: Meeting demands for innovations with an array of products and solutions

 

Supermicro President and CEO Charles Liang stated that Supermicro will continue to meet customer demand in terms of AI, 5G, and cloud solutions through its leading technology, innovation, high quality, and serviceability. Supermicro will also push forward the development of technology with its partners through collaborations.

 

NVIDIA: Igniting Industrial Revolution 4.0 with AI

 

According to Jerry Chen, NVIDIA Head of Global Business Development for Manufacturing and Industrials, AI is the most impactful general-purpose technology, and it will be at the heart of advanced technologies such as 5G, HPC, AIoT, and robotics, propelling industry development and transformation.

 

NXP Semiconductors: Accelerating Secure Intelligent Edge with New Era of Edge Computing Started

 

Kurt Sievers, President and CEO of NXP Semiconductors, indicated that AIoT devices are changing the way people live. While it creates great user experience, it is imperative to fully protect data and realize a secure intelligent edge. NXP Semiconductors will also continue to enable a safer and smarter world through breakthrough innovations.

 

Arm: Accelerating ubiquitous intelligence

 

Rene Haas, President of Arm IP Products Group, discussed the increasing global demand for computing. The new Armv9 architecture is effective in addressing demanding AI/ML workloads while delivering enhanced security. The next-gen architecture outlines the roadmap for the next decade of computing.

 

Intelligence-driven manufacturing for advancing into Industry 4.0

 

According to Dr. Steven Chen, Leader of Intelligent Mobile Machine Cluster, Delta Research Center of Delta Electronics, manufacturers must continue to improve their capabilities to achieve “Manufacturing on Demand.” By adopting design that incorporate standardized, modular and intelligent units, machines can be more scalable and flexible to production changes, as well as data collection & analysis and AI adoption and upgrade, accelerating the progress of an Intelligence-driven manufacturing.

 

Check Point Software: Managing cybersecurity risks through AI tool

 

Kev Hau, Check Point Security evangelist,　office of the CTO, shared his insights on the trend of cybersecurity in the new normal. AI, machine learning, and big data analytics are all revolutionizing cybersecurity. The machine-learning algorithm of AI is capable of predicting unknown threats in a much broader scope and providing cybersecurity specialists a quick response with increasing accuracy and precision.

 

AI is reshaping the world. With the democratization of related technologies and AIoT applications, COMPUTEX aims to explore more business opportunities with its global partners.

 

1. All sessions are available online from now: https://virtual.computextaipei.com.tw/events/
2. Register for free:

https://virtual.computextaipei.com.tw/

 

For more information: https://virtual.computextaipei.com.tw/events/

 

#########

 

For more information:

 

COMPUTEX : https://www.computextaipei.com.tw/

 

InnoVEX : https://www.innovex.com.tw/

 

About COMPUTEX

 

Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.

 

About COMPUTEX 2021 Virtual

 

As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnovexVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.

 

Explore #COMPUTEXVirtual now at https://virtual.computextaipei.com.tw/.

 

About TAITRA

 

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005420/en/

The content is by Business Wire India. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.

The post COMPUTEX Forum Day 1: Deep Diving into AI and AIoT appeared first on DKODING.

from https://www.dkoding.in/press-release/computex-forum-day-1-deep-diving-into-ai-and-aiot/
via Dkoding RSS Feed

Share:

Read More

Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg

MUMBAI, India, June 4, 2021 /PRNewswire/ — Glenmark Pharmaceuticals Ltd (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Theophylline Extended-release Tablets, 300 mg and 450 mg, bioequivalent and therapeutically equivalent to the reference listed drug, Theophylline Extended-Release Tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Limited.  

Glenmark has been granted a competitive generic therapy (CGT) designation for Theophylline Extended-release Tablets USP, 450 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing of the 450 mg strength.

According to IQVIA^TM sales data for the 12 month period ending April 2021, the Theophylline Extended-release Tablets, 300 mg and 450 mg  market¹ achieved annual sales of approximately $47.8 million.*

Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

References:

¹Market includes brand and all available therapeutic equivalents

*IQVIA^TM National Sales Perspectives: Retail & Non-Retail, April 2021

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index.

For more information, visit www.glenmarkpharma.com

Logo: http://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg  

The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.

The post Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg appeared first on DKODING.

from https://www.dkoding.in/press-release/glenmark-pharmaceuticals-receives-anda-approval-for-theophylline-extended-release-tablets-300-mg-and-450-mg-granted-competitive-generic-therapy-cgt-designation-and-is-eligible-for-180-days-of-cgt/
via Dkoding RSS Feed

Share:

Read More

Moody’s ESG Solutions: V.E provides Second Party Opinion on Edison International’s Sustainable Financing Framework

Business Wire India

Moody's ESG Solutions announced today that V.E has provided a Second Party Opinion (SPO) on Edison International’s Sustainable Financing Framework. The framework will govern future bond issuances to finance environmental and social project categories.

 

The eligible green projects aim to combat climate change through the avoidance of CO2 emissions, increase resilience to the physical effects of climate change, and improve energy efficiency. The eligible social projects intend to reduce inequality by enabling opportunities in Edison’s procurement for diverse business enterprises, such as small businesses that are owned by minority communities, women, veterans, and/or the LGBTQ+ community.

 

According to V.E, Edison’s framework is aligned with the four core components of the Green Bond Principles, Social Bond Principles and Sustainable Bond Guidelines.

 

“In our assessment, the bonds issued via this framework will provide an ‘advanced’ contribution to sustainability objectives,” said Adriana Cruz Felix, Head of Sustainable Finance Research at V.E. “Integrating renewable sources on the grid and supporting customers’ adoption of carbon-free technology are some of the key issues facing the electric utility sector – the renewable energy projects to be financed via Edison’s framework have the potential to positively impact the company, its supply chain and customers.”

 

V.E’s SPOs on sustainability credentials help market participants secure financing through sustainable bonds and loans, strengthen issuers’ and projects’ credibility, and give investors confidence. To date, V.E has produced more than 330 SPOs on sustainable financing operations worldwide. To learn more, please visit moodys.com/sustainable-finance.

 

V.E’s SPO on Edison International’s Sustainable Financing Framework is available here.

 

ABOUT MOODY’S ESG SOLUTIONS

 

Moody’s ESG Solutions Group is a business unit of Moody’s Corporation serving the growing global demand for ESG and climate insights. The group leverages Moody’s data and expertise across ESG, climate risk, and sustainable finance, and aligns with Moody's Investors Service (MIS) and Moody's Analytics (MA) to deliver a comprehensive, integrated suite of ESG and climate risk solutions including ESG scores, analytics, Sustainability Ratings and Sustainable Finance Reviewer/certifier services.

 

For more information visit Moody’s ESG hub at www.moodys.com/esg.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005436/en/

The content is by Business Wire India. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.

The post Moody’s ESG Solutions: V.E provides Second Party Opinion on Edison International’s Sustainable Financing Framework appeared first on DKODING.

from https://www.dkoding.in/press-release/moodys-esg-solutions-v-e-provides-second-party-opinion-on-edison-internationals-sustainable-financing-framework/
via Dkoding RSS Feed

Share:

Read More